Objective: To establish a reasonable and stable mouse model of hyperuricemia renal damage, and to provide a pathological model for screening and researching drugs for the treatment of hyperuricemia nephropathy?
Method: Potassium oxalate? Xanthine? Ardenning? Do you use 5 styling agents alone for Etambutor and Yeast Cream? Do you use a combination of two drugs or a combination of three drugs? Do you observe different modeling times? Modeling dose and modeling method. Is a serum kidney injury model established for the levels of uric acid, urea nitrogen and creatinine in mice with hyperuricemia? Changes in the activity of liver xanthine oxidase (XOD) and adenosine deaminase (ADA)? What are the pathological changes and weight changes of the kidneys in each group?
Result: Compared with the normal group, the serum uric acid level and urea nitrogen of the single model mice combined with hypoxanthine and potassium oxazine were significantly increased (P\u003c0.01), and renal tubular casting was observed. Crystals of salt found in renal cortex and renal medulla; when combined with hypoxanthine, etabaol and potassium oxalate in mice of 7d group, serum uric acid level and urea nitrogen are normal, circumflex branch It was found that liver XOD activity was significantly increased (P\u003c0.01), liver XOD activity was significantly reduced (P\u003c0.05), renal eosinophilic insoluble protein and yeast extract and potassium oxalate 14d group and yeast extract, Compared with the 14d group of adenine and potassium oxalate, the serum uric acid, urea nitrogen and creatinine levels of mice were significantly increased (P\u003c0.01). In the yeast cream plus potassium oxalate group, renal tubular epithelial cells were shed, and eosinophil insoluble proteins were found in the proximal gyrus of the kidney, yeast cream, adenine and potassium oxalate. The kidney medulla of this group of mice has salt crystals, the combination of yeast cream and potassium oxalate gains weight faster than the combination of yeast cream, adenine and potassium oxalate, and the difference between the two groups is greater.
Conclusion: Compared with other modeling methods, the hyperuricemia kidney injury mouse model established by the combined use of yeast extract and potassium oxalate is more stable and has a significant impact on the body weight of the mice. Since the modeling method is more in line with clinical characteristics, is it more appropriate to use yeast cream and potassium oxalate to establish a 14-day mouse model of hyperuricemia nephropathy?